← FDA ENFORCEMENT
D-0620-2024Class I

SoloVital

Recalling firm
SoloVital
Product type
Drug
Status
Ongoing
Report date
2024-08-07
Distribution
Nationwide within the United States
Firm state
CA
Product quantity
1,331 bottles
Initiated by
Voluntary: Firm initiated
SPEQ quality domain
Documentation & Change Control
Reason for recall

Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.

Product description

Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles.

Code / lot info

All lots within Expiry

Other recalls SPEQ maps to Documentation & Change Control
2026-07-22Class IIDaavlin Distributing Company2026-07-22Class IIOrthofix U.S. LLC2026-07-22Class II3B Medical, Inc.2026-07-22Class IIDaavlin Distributing Company
See all Documentation & Change Control recalls →

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.